ATRA vs. ENTX, CVM, TARA, TIL, CGTX, TSBX, DTIL, ELUT, IKNA, and JATT
Should you be buying Atara Biotherapeutics stock or one of its competitors? The main competitors of Atara Biotherapeutics include Entera Bio (ENTX), CEL-SCI (CVM), Protara Therapeutics (TARA), Instil Bio (TIL), Cognition Therapeutics (CGTX), Turnstone Biologics (TSBX), Precision BioSciences (DTIL), Elutia (ELUT), Ikena Oncology (IKNA), and JATT Acquisition (JATT). These companies are all part of the "biological products, except diagnostic" industry.
Atara Biotherapeutics (NASDAQ:ATRA) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment, community ranking and analyst recommendations.
In the previous week, Entera Bio had 12 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 12 mentions for Entera Bio and 0 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.00 beat Entera Bio's score of -0.15 indicating that Atara Biotherapeutics is being referred to more favorably in the media.
Entera Bio has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -671.70%. Entera Bio's return on equity of -103.40% beat Atara Biotherapeutics' return on equity.
70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 14.1% of Entera Bio shares are held by institutional investors. 4.5% of Atara Biotherapeutics shares are held by insiders. Comparatively, 8.9% of Entera Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Atara Biotherapeutics currently has a consensus price target of $28.00, indicating a potential upside of 4,490.16%. Entera Bio has a consensus price target of $10.00, indicating a potential upside of 309.84%. Given Atara Biotherapeutics' higher probable upside, research analysts plainly believe Atara Biotherapeutics is more favorable than Entera Bio.
Entera Bio has lower revenue, but higher earnings than Atara Biotherapeutics. Entera Bio is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Atara Biotherapeutics received 255 more outperform votes than Entera Bio when rated by MarketBeat users. Likewise, 67.67% of users gave Atara Biotherapeutics an outperform vote while only 66.92% of users gave Entera Bio an outperform vote.
Atara Biotherapeutics has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, Entera Bio has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500.
Summary
Entera Bio beats Atara Biotherapeutics on 11 of the 18 factors compared between the two stocks.
Get Atara Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atara Biotherapeutics Competitors List
Related Companies and Tools
